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The ESNLG had its origins in an Edinburgh
Lymphoma Group formed in 1973 to promote the
co-operative management and investigation of
lymphoma by pooling resources for data collection
and encouraging collaborative studies. Aberdeen,
Inverness, Dundee and Perth joined in 1975 and
Newcastle in 1978 to form the present group, which
has been supported by local charities, the Scottish
Home and Health Department and the Cancer
Research Campaign.
The aim of the Second National meeting of the
Group was to provide a forum for exchanging
information with other clinicians and pathologists
in the U.K. The first meeting was held in 1978, but
in future further national meetings will be held at 3
yearly intervals.
The symposium opened with a review of the
potential of immunohistochemistry in aiding the
diagnosis of non-Hodgkin's lymphomas on fresh
and fixed material. K. Gatter (Oxford) reported that
in adults, the usual problem is to distinguish
lymphoma from anaplastic carcinoma where
morphology alone can be not only unhelpful but
even misleading. He placed particular emphasis on
the progress which has been made in applying
monoclonal antibodies to routinely fixed paraffin
embedded tissues. The rest of the introductory
session focused on the management of high grade
non-Hodgkin's lymphoma and R.C.F. Leonard
(Edinburgh) surveyed the current clinical
management of high grade lymphoma emphasising
the dismal long term survival in comparison with
the progress in the management of Hodgkin's
disease. He pointed out that improving these
survival data depends upon improving the quality
of the cytotoxic chemotherapy and that genuinely
localised NHL can be cured by local treatment.
Improving the efficacy of cytotoxic chemotherapy
probably depends upon adopting more flexible
strategies and in some instances using cytotoxic
drugs "mid-cycle" for the tumours with a very high
rate of proliferation. American regimes which have
adopted these principles (e.g. promace-MOPP and
M-BACOD) appear to induce higher response rates
although the long term survival effect is unknown.
Western General Hospital, Edinburgh EH4 2XU.
It is not clear that these approaches will suit all
patients with high grade NHL and there is much to
be gained from analysis of prognostic factors
outside histopathology such as systemic symptoms,
performance status, possibly biochemical factors,
when trying to evaluate the comparability between
treatment groups.
S.J. Proctor (Newcastle) reiterated the problem
that high remission rates did not necessarily
translate into long term survival and he reviewed
the data of recent pilot experiments which included
bone marrow transplantation whether allogeneic,
syngeneic or autologous, for the treatment of
lymphoma using high doses of chemotherapy and
radiotherapy. He drew an analogy between the
current situation in lymphoma and that in acute
leukaemia when bone marrow transplantation was
undertaken at relapse or second remission. He
speculated that this therapeutic approach remained
a useful avenue for exploring new chemotherapy
and radiotherapy combinations with the added
advantage of manipulating the explanted bone
marrow in vitro using immunological techniques.
Nevertheless, before such approaches can be widely
tested in the clinic detailed experiments need to be
conducted on the most effective ways of removing
malignant populations of cells by in vitro
techniques.
In the next session the immunology and virology
of human lymphoma was reviewed. G. Bird
(Newcastle) pointed to the association of malignant
lymphoma with primary and secondary immuno-
deficiency syndromes and emphasised the restricted
nature of the malignant diseases that arise in these
situations. Non-Hodgkin's lymphomas are pre-
dominant but vary according to the nature of the
immune deficiency syndrome so that in X-linked
agammaglobulinaemia the incidence of NHL is as
low as 0.7% but rises to 35% in the X-linked
lymphoproliferative syndrome. Intermediate
between these two levels of incidence, but exhibiting
a marked increase propensity to secondary
lymphoma are the other primary immunodeficiency
diseases, the Wiskott-Aldrich syndrome, X-linked
hypogammaglobulinaemia with hyper IgM,
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ataxia telangiectasia and common variable hypo-
gammaglobulinaemia. All exhibit a degree of T
lymphocyte impairment and in some cases natural
killer cell deficiency. Organ transplant recipients
form a recent group of secondary immunodeficient
patients and the appearance of B cell lymphomas
following cyclosporin A-induced immuno-
suppression strongly implicates EB virus at least as
a co-factor in the initiation of the malignancy. The
common mechanism, regardless of cause may be
prolonged T cell function impairment followed by
EBV virus-associated B cell neoplastic trans-
formation.
C.M. Steel (Edinburgh) further elaborated on the
association of EB virus with Burkitt's lymphoma
both from epidemiological studies in Africa and
New Guinea and from the direct isolation of the
virus in laboratory cultures of lymphoblastoid cells.
There are endemic areas of Burkitt's lymphoma in
Africa and New Guinea where EBV is highly
associated but equally in Europe and North
America sporadic cases of Burkitt's lymphoma are
usually EBV negative. Other areas of North Africa
have intermediate incidences of Burkitt's lymphoma
and intermediate levels of EBV-association. There is
at present no convincing evidence that EBV is the
agent which causes the chromosomal (t8:14)
transformation that characterises the cells of EBV-
positive and EBV-negative Burkitt's lymphoma.
These data and those from immune-deprived
patients in whom EBV infection may cause a
polyclonal (sometimes eventually monoclonal) and
fatal B cell lymphoproliferative condition, suggest
that EBV constitutes at least one element in the
multi-stage progression from normal function to
malignancy of B lymphocytes.
G. Stockdill (Edinburgh) reported a case of adult
T cell leukaemia-lymphoma in association with
evidence of previous infection with a retrovirus that
demonstrated strong positivity with a monoclonal
antibody (P19) directed against the core protein of
human T cell leukaemia virus (HTLV1). Gene
probes failed to confirm this as being HTLV1 or
HTLV2 but the possibility of this being a further
variant is likely and emphasised the need for
checking this aspect in patients with T cell
malignancy.
J.C. Neil (Glasgow) reviewed the possible
mechanisms involved in the oncogenic trans-
formation of cell lines by reference to the ras
oncogenes. He reiterated the possibility of a
multiple gene activation by pointing to the
observation that two or more oncogene mutations
may occur in a given human tumour cell line
providing further evidence that "natural" malignant
transformation of B cells may be a multi-step
process involving oncogene alterations.
The next section of the symposium focused on
the sequelae of lymphoma and those attendant
upon treatment of lymphoma. P.D.G. Davey
(Dundee) has found a high incidence of subclinical
thyroid dysfunction, judged by assessment of T3,
T4, TRH and thyroid antibody levels in 18 patients
with Hodgkin's disease treated by radiotherapy to
the neck. By comparing the incidence with that seen
in laryngeal carcinoma, similarly treated, he
concluded that the high incidence in Hodgkin's
disease might be the result of a combination of
iodine load from lymphangiography followed by
radiotherapy, or could be related to the disease
itself or possibly to the lower age of the population,
rendering them relatively more susceptible to these
radiotherapy effects. Another series of Hodgkin's
disease patients who had received no radiotherapy
but who had had lymphangiography had a
significantly lower incidence of detectable thyroid
dysfunction.
N.B. Bennett (Aberdeen) reviewed the effect of
chemotherapy and radiotherapy on fertility. Radio-
therapy did not materially affect fertility, with 80%
of young women so treated subsequently achieving
pregnancy and the remaining 20% showing
hormonal evidence *of normal ovarian function.
Likewise, after radiotherapy 52% of young males
had later fathered children or had normal spern
counts. The remaining 48% of young men either
refused to supply sperm for analysis or had
declared that their family was already complete. All
patients, of either sex, showed intact pituitary and
gonadal function by endocrine analysis. However,
chemotherapy strikingly impairs male fertility.
Between 2 and 48 months following chemotherapy
all men tested were azoospermic with elevated FSH
levels but normal LH and testosterone levels. By
contrast, 50% of women so treated were actually -or
potentially fertile (20% pregnant, 30% normal
endocrine function). Seventy-five per cent of women
who had been on the contraceptive pill during
chemotherapy retained evidence of fertility against
only 43% fertile or potentially fertile of those who
had not been on the contraceptive pill. The mean
age of those still fertile post-treatment was 24 and
for the infertile 31. Further analysis of these factors
contributing to the retention of fertility is
confounded by the considerable overlap of young
age and oral contraceptive use. Thus whereas
localised radiotherapy had no effect upon fertility,
chemotherapy results in prolonged azoospermia in
men whilst in women its influence depends on the
woman's age whether or not she continues to take
oral contraceptives during the cytotoxic chemo-
therapy.
J.E. Kingston (London) emphasised that patients
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disease as the primary lymphoid malignancy) have
a higher risk of second malignancy following
treatment (-280 per 100,000 patients per annum
post-Hodgkin's disease against a 131 per 100,000
patients per annum post-non-Hodgkin's lymphoma)
(Mike, V., et al. (1982) Lancet, ii, 1326-1330). The
U.K. Childhood Cancer Research Group data
support these findings; in the period from 1962-
1977 9/790 children with Hodgkin's disease later
developed a second malignancy against 1/1,275
children who had had non-Hodgkin's lymphoma
over the same period.
The psychological impact of lymphoma was
discussed by Miss J. Devlen who studied patients in
Manchester. Sixty-three per cent of patients
interviewed had some degree of anxiety and/or
depression much of it associated with the initial
diagnosis and early treatment. However significant
morbidity arises later in the disease with problems
arising from the disruption to life due to hospital
visits, conditioned nausea and vomiting due to
treatment, memory impairment and physical
symptoms.
The final formal session concerned extral nodal
lymphoma. A. Parker (Edinburgh) identified only 20
pure extra nodal against 36 nodal and extra nodal
mixed and 328 purely nodal presentations from
Hodgkin's disease in ESNLG population from
1979-1983. The truly "extra nodal only" Hodgkin's
patients are probably even rarer when more
carefully evaluated. By comparison, out of 845
evaluable non-Hodgkin's lymphomas, 309 were
extra nodal and 105 mixed extra nodal with nodal
at presentation. Following further evaluation the
309 "mainly extra nodal" could be reduced to 136
purely extra nodal lymphomas.
G.R.P. Blackledge (Birmingham) illustrated the
problems of staging and treating gastrointestinal
lymphoma. Most patients have high grade
malignancy tumours and radiology is often
unhelpful with staging dependent upon careful
surgical evaluation at biopsy or resection of the
primary tumour. Genuinely local disease may be
cured surgically whereas others require chemo-
therapy and radiotherapy. He reported that in the
West Midlands studies are directed at evaluating
the place for low dose chemotherapy at the start of
treatment to reduce the acute morbidity and
mortality that often attends the use of standard
doses of drugs, due to perforation of the bowel
wall. He also suggested that more surgically based
staging classification would be more valuable than
trying to apply the Ann Arbor system.
B.W. Hancock (Sheffield) reported 21 cases of
non-Hodgkin's lymphoma and 5 cases of Hodgkin's
disease- arising primarily in the central nervous
system in a population of 396 patients (173 cases of
Hodgkin's disease, 223 of non-Hodgkin's lym-
phoma). Brain, meningeal and extradural involve-
ment was seen in non-Hodgkin's lymphomas
whereas the 5 cases of Hodgkin's disease had
presentations confined to the extradural tissues of
the spinal cord. No cases of Hodgkin's disease were
confined to the central nervous system. In all cases
good recovery is possible with appropriate radio-
therapy, chemotherapy and sometimes surgery.
Meningeal relapse in non-Hodgkin's lymphoma
however, is usually fatal. There is a case for central
nervous system prophylaxis in some young patients
with high grade non-Hodgkin's lymphomas. The
differential diagnosis of neurological syndromes in
these patients includes iatrogenic causes, para-
neoplastic events including progressive multi focal
leuko encephalopathy and infection.
G.W. Beveridge (Edinburgh) concluded the session
by reviewing the dermatological syndromes caused
by non-Hodgkin's lymphomas. He pointed to the
diagnostic problems involved and noted that
whereas B cell lymphomas are only manifested in
skin late on in the course of the illness, T cell
lymphomas, often arising in skin, may be confined
to this organ for years. At these early stages PUVA
and local radiotherapy can be very effective. After
reviewing the special features of mycosis fungoides
and the Sezary syndrome, he concluded that
immunological techniques may be valuable in
improving the diagnostic sensitivity of skin biopsies
with the aim of improving staging and the
evaluation of therapy.
This report has concentrated on the formal
presentations although there was a useful poster
session and a well attended and enthusiastically
received debating session which was devoted to the
topic, "Staging: laparotomy has no part of play in
the mangement of Hodgkin's disease" (for the
motion A. Jeliffe, London against, A. Brewin,
Glasgow). A second debate, "Chemotherapy has no
role in the management of low grade non-
Hodgkin's lymphomas" (for the motion A. Lister,
London, against the motion, J.G. MacVie,
Amsterdam), was attended by a lively discussion.